Bioxcel therapeutics presents positive data from phase 2 trial of bxcl701 in aggressive forms of prostate cancer at 2022 asco genitourinary cancers symposium

Bxcl701 plus keytruda® (pembrolizumab) demonstrates encouraging composite response rates in scnc (33%) and adenocarcinoma (21%) cohorts

BTAI Ratings Summary

BTAI Quant Ranking